Risk for Esophageal Adenocarcinoma Not Increased With Nonerosive GERD
WEDNESDAY, Sept. 20, 2023 -- Patients with nonerosive gastroesophageal reflux disease (GERD) do not have an increased risk for esophageal adenocarcinoma compared with the general population, according to a study published online Sept. 13 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2023 Category: Pharmaceuticals Source Type: news
Non-Erosive GERD May Not Increase Risk of Esophageal Cancer
(MedPage Today) -- Patients with non-erosive gastroesophageal reflux disease (GERD) appear to have a similar incidence of esophageal adenocarcinoma as the general population, according to a large Nordic population-based cohort study with up to... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 18, 2023 Category: Gastroenterology Source Type: news
Methylation Score Can ID Risk for Cervical Adenocarcinomas
WEDNESDAY, Sept. 13, 2023 -- A methylation score, composed of the average methylation percentage across 35 CpG sites in the L2/L1 open reading frames of human papillomavirus (HPV)16, 18, and 45, and two human loci, can identify the risk for cervical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 13, 2023 Category: Pharmaceuticals Source Type: news
Large-Scale Investigation Supports Modified Classification System for Pulmonary Adenocarcinomas
A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the International Association for the Study of Lung Cancer (IASLC) 2023... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 11, 2023 Category: Pharmaceuticals Tags: TRI SVY Source Type: news
Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care
(MedPage Today) -- An intratumoral drug-releasing microdevice implanted in glioma patients can measure the drug's antitumor effects and could potentially help guide treatment, early data suggest. (Brigham and Women's Hospital, Science Translational... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 7, 2023 Category: Hematology Source Type: news
Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
FRIDAY, Sept. 1, 2023 -- For patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma, zolbetuximab, a monoclonal antibody that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2023 Category: Pharmaceuticals Source Type: news
AI Tool Predicts Certain GI Cancers Years in Advance AI Tool Predicts Certain GI Cancers Years in Advance
A machine learning tool embedded in the electronic health record accurately predicted esophageal adenocarcinoma and gastric cardia adenocarcinoma years before diagnosis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 29, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Drug that targets scar-like tissue in tumours shows promise for aggressive pancreatic cancer
Findings from the Garvan Institute of Medical Research reveal a new Australian drug that targets scar-like 'fibrotic' tissue within tumours shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer with a five-year survival rate of less than 10%.
The research in mouse models showed that when given in combination with chemotherapy, the drug PXS-5505 increased survival time by more than 35%, compared to chemotherapy treatment alone. (Source: World Pharma News)
Source: World Pharma News - August 29, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
K-ECAN Tool Can Predict Esophageal, Gastric Cardia Adenocarcinoma
MONDAY, Aug. 28, 2023 -- The Kettles Esophageal and Cardia Adenocarcinoma predictioN (K-ECAN) Tool can predict incident esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA) using electronic health record data, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 28, 2023 Category: Pharmaceuticals Source Type: news
Rate of Positive Laparoscopy High for Patients With Pancreatic Cancer
TUESDAY, Aug. 15, 2023 -- For patients with pancreatic ductal adenocarcinoma (PDAC), the rate of positive laparoscopy (PL) is high and is associated with younger age, indeterminate extrapancreatic lesions on preoperative imaging, and body/tail tumor... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 15, 2023 Category: Pharmaceuticals Source Type: news
Mutations May Predict Progression From Barrett's to Cancer Mutations May Predict Progression From Barrett's to Cancer
Certain genetic mutations were more common among patients with Barrett esophagus whose condition progressed to esophageal adenocarcinoma, suggesting the usefulness of genetic sequencing in this population.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 10, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mesothelioma Immunotherapy Receives Orphan Drug Designation
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration.
Avenge Bio, a biotechnology company working on a new treatment platform for immunotherapy, announced it was granted the designation for its drug AVB-001 in June. It is currently enrolling patients in ongoing phase 1 and phase 2 clinical trials for the treatment of advanced ovarian cancer, primary peritoneal mesothelioma and fallopian tube cancer.
AVB-001 is a new treatment being developed by Avenge Bio using its LOCOcyte immunotherapy platform to treat solid tumors. It’s a first-in-human, si...
Source: Asbestos and Mesothelioma News - August 9, 2023 Category: Environmental Health Authors: Lynette Zilio Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
One-Fourth of Esophageal Cancers Among Those With BE Missed in Year Before Diagnosis
FRIDAY, Aug. 4, 2023 -- Nearly one-quarter of Barrett esophagus patients with esophageal adenocarcinoma (EAC) had normal endoscopic screenings within the prior year, according to a study published online June 4 in Gastroenterology.
Sachin Wani,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 4, 2023 Category: Pharmaceuticals Source Type: news
Too Many Pancreatic Cancer Patients Not Offered Surgery
FRIDAY, July 28, 2023 -- Surgery is underutilized for the treatment of resectable pancreatic ductal adenocarcinoma (PDAC) in Texas, according to a study recently published in the Journal of Surgical Oncology.
Gilbert Z. Murimwa, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 28, 2023 Category: Pharmaceuticals Source Type: news
How Staging Laparoscopy Informs Pancreatic Cancer Care How Staging Laparoscopy Informs Pancreatic Cancer Care
Researchers recommend staging laparoscopy for most patients with localized pancreatic ductal adenocarcinoma prior to resection to determine the stage of cancer and metastatic disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
